ASCO GI Featured Voice: Dr. Supriya Peshin on Research, Women in Oncology, and More
By Supriya Peshin, MD - Last Updated: January 29, 2025At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Supriya Peshin, MD, resident physician at Ballad Health and an ASCO GI Featured Voice, gives her thoughts on the future of GI oncology and the research that she found most interesting at the 2025 conference.
Advertisement
Advertisement
Related Posts
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.